Age-related diseases, therapies and gut microbiome: A new frontier for healthy aging.

Age-related diseases Aging Anti-age therapies Gut microbiome Microbiome-based therapies

Journal

Mechanisms of ageing and development
ISSN: 1872-6216
Titre abrégé: Mech Ageing Dev
Pays: Ireland
ID NLM: 0347227

Informations de publication

Date de publication:
09 2022
Historique:
received: 21 02 2022
revised: 17 07 2022
accepted: 18 07 2022
pubmed: 23 7 2022
medline: 10 8 2022
entrez: 22 7 2022
Statut: ppublish

Résumé

The gut microbiome is undoubtedly a key modulator of human health, which can promote or impair homeostasis throughout life. This is even more relevant in old age, when there is a gradual loss of function in multiple organ systems, related to growth, metabolism, and immunity. Several studies have described changes in the gut microbiome across age groups up to the extreme limits of lifespan, including maladaptations that occur in the context of age-related conditions, such as frailty, neurodegenerative diseases, and cardiometabolic diseases. The gut microbiome can also interact bi-directionally with anti-age-related disease therapies, being affected and in turn influencing their efficacy. In this framework, the development of integrated microbiome-based intervention strategies, aimed at favoring a eubiotic configuration and trajectory, could therefore represent an innovative approach for the promotion of healthy aging and the achievement of longevity.

Identifiants

pubmed: 35868543
pii: S0047-6374(22)00093-8
doi: 10.1016/j.mad.2022.111711
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111711

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Monica Barone (M)

Microbiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy; Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy. Electronic address: monica.barone@unibo.it.

Federica D'Amico (F)

Microbiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy; Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy. Electronic address: federica.damico8@unibo.it.

Simone Rampelli (S)

Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy. Electronic address: simone.rampelli@unibo.it.

Patrizia Brigidi (P)

Microbiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy. Electronic address: patrizia.brigidi@unibo.it.

Silvia Turroni (S)

Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy. Electronic address: silvia.turroni@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH